[Effect of the antirheumatic drug Sulindac on thrombocyte function (author's transl)].
The effect of a treatment with the antirheumatic drug Sulindac (from 200 to 400 mg/day over 4 weeks) on thrombocyte function (bleeding time, platelet retention, platelet aggregation induced with suitable concentrations of ADP, epinephrine, collagen and Ristocetin) on thrombocyte count and thromboplastin time was investigated in 20 patients. In 10 healthy volunteers collagen-induced platelet aggregation was measured after oral application of 200 mg Sulindac. Analysis of the data obtained by the tests revealed no unwanted or harmful effects of Sulindac on platelet functions, platelet count and prothrombin time. No significant difference between the data before and during treatment was found. No medical drop out was registrated.
D003094:Collagen; D006801:Humans; D007192:Indenes / Q000494:pharmacology*; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D010976:Platelet Count; D013467:Sulindac / Q000494:pharmacology*
D007192:Indenes; D013467:Sulindac; D003094:Collagen
Die Thrombozytenfunktion unter dem Antirheumatikum Sulindac.